Report post
ABBV-400, a c-Met-targeting antibody-drug conjugate (ADC), has shown promising Phase 1 results in various cancer treatments. In previously treated metastatic colorectal cancer (mCRC) with fluorouracil, folinic acid, and bevacizumab, it demonstrated efficacy. In advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) and EGFR wild-type (WT) non-squamous non-small cell lung cancer (NSCLC), ABBV-400 also exhibited potential, positioning it as a promising next-generation ADC for lung cancer treatment.

The World's Leading Crypto Trading Platform

Get my welcome gifts